GHK-Cu is a copper-bound tripeptide studied mostly in skin, collagen and matrix biology. BPC-157 is a 15-amino-acid sequence studied mostly in animal gut, tendon and nerve models. Both carry published literature. Neither has ever been tested against the other inside a single experiment.
The short answer
Seven published records discuss GHK-Cu and BPC-157 together. Every one is a secondary synthesis of other people's work. Not one gave either compound to anything.
That gap shapes the rest of this page. GHK-Cu research centres on skin and matrix signalling, and it reached human trials decades ago. The two largest returned null results on their objective endpoints (PMIDs 1495150, 16847171). BPC-157 research centres on animal models of gut, tendon, bone and nerve injury. Its human record runs to five small studies identified by the FDA, one controlled and published only as a conference abstract.
Their regulatory positions differ by route. Non-injectable GHK-Cu sits in FDA Category 1, injectable GHK-Cu does not, BPC-157 in neither.
Last verified 22 October 2026. Sources checked include PubMed, the FDA nominations document and safety risks page, the WADA Prohibited List, and Health Canada advisories. Prepared by the PrimeTime BioLabs editorial team. A named medical reviewer has not yet been assigned.
Seven reviews put these two side by side and not one experiment has
One PubMed search, run on 22 October 2026, returns seven records. The string was ("GHK-Cu" OR "glycyl-histidyl-lysine" OR "copper peptide GHK") AND ("BPC-157" OR "body protection compound"). They span regenerative medicine, sports medicine, orthopaedics, gerontology and aesthetics.
All seven are secondary literature syntheses. Not one of them is an experiment. Each treats the two compounds in separate sections, and none measures them against a shared endpoint.
Broadening the search does not change the answer. Wider synonyms on both sides return the identical seven. A search built around combination terms returns none at all.
Reviews can establish that two bodies of work exist and that somebody surveyed them. They cannot establish that either compound outperforms the other, because no review holds data of its own.
GHK-Cu reached people, and the two largest trials came back null
The largest human trial of a copper tripeptide treated venous stasis ulcers in 86 evaluable patients (PMID 1495150). It ran three arms with evaluators blinded. Silver sulfadiazine 1% cream significantly reduced ulcer size. Copper tripeptide 0.4% cream did not differ from inert vehicle placebo.
A second trial followed patients through circumoral CO2 laser resurfacing (PMID 16847171). Thirteen patients completed the full course. Erythema resolution showed no significant difference, measured by software and by blinded evaluators. Wrinkle improvement and rated skin quality at 12 weeks showed none either. Only one endpoint reached statistical significance. Patients rated their own skin quality higher on a validated questionnaire, at P = .04.
Several records cited as GHK-Cu evidence do not test GHK-Cu. One used ALAVAX, a 5-aminolevulinic acid and GHK complex, where the lower dose arm outperformed the higher (PMID 27489425). Another used a six-ingredient injectable cocktail with no control (PMID 29482481). Two tested cosmetic products, both authored in part by the company selling them (PMIDs 39449909, 41001334). None of them isolates the peptide's contribution.
A 2026 systematic review of GHK-Cu in aesthetic medicine found the evidence mostly preclinical, with few well-designed clinical trials (PMID 42619529).
Our GHK-Cu explainer covers the chemistry in depth. Much of the mechanistic literature shares one affiliation. Loren Pickart's reviews list Skin Biology, a copper-peptide skincare company (PMIDs 26236730, 29986520). Those are reviews by a commercially interested author, and they do not corroborate each other independently.
BPC-157 has 235 records and a Phase 1 that never reported
A PubMed search for "BPC-157" OR "body protection compound" returns 235 records. Record count and evidence quality are separate things, and the gap is wide.
The FDA identified five published human studies in its May 2026 briefing. They cover rectal enema in healthy subjects and in ulcerative colitis, plus intra-articular injection for knee pain. The remaining two are intravesical injection for interstitial cystitis, and intravenous infusion in two healthy adults. One was randomised and placebo-controlled, with 53 subjects given as total randomised enrolment, and it exists only as a meeting abstract.
Just one Phase 1 trial sits on the registry, NCT02637284, which tested oral PCO-02 in healthy volunteers. Its status reads "unknown", meaning the entry stopped being updated past expected completion. That does not mean the trial completed, and no results were posted. A University of Arkansas study of BPC-157 in rotator cuff repair is registered as not yet recruiting, with a start estimated in January 2027 (NCT07803250).
No receptor or molecular target has been identified for BPC-157. The group that originated the compound says so itself, describing a network of interconnected evidence in place of direct conclusive proof. FDA's briefing agrees, and adds that it found no studies formally investigating immunogenicity.
Our BPC-157 explainer grades that literature in more depth.
Where the two literatures actually touch, and why that still isn't a comparison
The verified literature supports twelve model families across the two compounds. Ten belong to one compound alone.
- Human laser-resurfaced skin — GHK-Cu evidence: RCT, 13 completed, null (16847171) — BPC-157 evidence: None — Direct comparison: No
- Human venous ulcer — GHK-Cu evidence: RCT, 86 evaluable, no better than placebo (1495150) — BPC-157 evidence: None — Direct comparison: No
- Human hair and scalp — GHK-Cu evidence: Three records, none isolating GHK-Cu (27489425, 29482481, 39449909) — BPC-157 evidence: None — Direct comparison: No
- Human scar and texture — GHK-Cu evidence: Uncontrolled, company-authored blend (41001334) — BPC-157 evidence: None — Direct comparison: No
- COPD plasma and muscle — GHK-Cu evidence: Human observational, cell, animal (36905132) — BPC-157 evidence: None — Direct comparison: No
- Rodent wound-chamber matrix — GHK-Cu evidence: Rat chamber with sequence control (8227353, 11121126, 10383745) — BPC-157 evidence: None — Direct comparison: No
- Chondrocyte and fibroblast culture — GHK-Cu evidence: Modified peptide forms (8562779, 11121126) — BPC-157 evidence: Tendon fibroblast, HUVEC (21030672, 25995620) — Direct comparison: No
- Rodent connective tissue — GHK-Cu evidence: One rat ACL record, benefit gone by 12 weeks (25731775) — BPC-157 evidence: Rat Achilles, active comparator, rabbit bone defect (14554208, 18594781, 10071911) — Direct comparison: No
- Burn and laser skin injury — GHK-Cu evidence: Human post-laser null, rat flap null (16847171, 23744835) — BPC-157 evidence: Mouse burn, mouse CO2 laser, rat alkali burn (11718984, 15774286, 25995620) — Direct comparison: No
- Gastrointestinal mucosa — GHK-Cu evidence: None — BPC-157 evidence: Colitis, anastomosis, fistula (7815358, 9403790, 26872976) — Direct comparison: No
- Peripheral nerve — GHK-Cu evidence: None — BPC-157 evidence: Rat sciatic transection (19903499) — Direct comparison: No
- Incisional pain — GHK-Cu evidence: None — BPC-157 evidence: Rat plantar incision, short-lived (35449779) — Direct comparison: No
Two families carry data on both sides. Neither of them permits a comparison.
Rodent connective tissue looks shared and is not. BPC-157 has Achilles transection work, a study using methylprednisolone as an active comparator, and a rabbit bone defect matched against autologous graft. GHK-Cu has one record, a rat ACL reconstruction in 72 animals. Knee laxity and graft stiffness improved at six weeks, then the advantage vanished by twelve. The authors put the word transiently in their title. Models, routes, endpoints and laboratories all differ.
Burn and laser injury holds the closest adjacency anywhere. BPC-157 was tested on CO2 laser skin injury in mice and improved healing (PMID 15774286). GHK-Cu was tested on CO2 laser resurfaced skin in people and improved no objective endpoint (PMID 16847171). The injury modality matches and the results point opposite ways. Species and evidence tiers differ, and nobody ran them together. That is an adjacency worth noticing, and it is not a comparison.
Diabetic wound healing is sometimes listed as shared territory, and it does not qualify. The GHK side rests on biotinylated GHK in a collagen matrix, a different chemical entity in a different vehicle (PMID 17049946).
One caution applies to the BPC-157 column. Most of its tendon, muscle, nerve, bone and gut records come from one research group in Zagreb. Many report equivalent effects across doses spanning three orders of magnitude.
One compound has two human trials, the other has five small studies and one conference abstract
- Human randomised controlled trial — GHK-Cu: Two, both null on objective endpoints — BPC-157: One, published only as a conference abstract
- Human uncontrolled or observational — GHK-Cu: Hair, scar and COPD records, none isolating the compound — BPC-157: Four of the five FDA-identified studies
- Animal — GHK-Cu: Wound chamber, rat flap, rat ACL, mouse muscle — BPC-157: Tendon, muscle, bone, nerve, gut, burn
- Cell and ex vivo — GHK-Cu: Fibroblast and chondrocyte culture — BPC-157: Tendon fibroblast, HUVEC
- Analytical and computational — GHK-Cu: Mechanistic and computational work — BPC-157: None carried here
A higher tier is not the same as performing better. GHK-Cu holds the human randomised row, and both entries there returned null results on the objectively measured endpoints. BPC-157 holds that row through one abstract carrying too little detail to assess.
The table shows where each literature stopped. It does not rank the compounds, because no study in either column was built to answer that question.
Nobody has given them together, and the stack talk comes from shops
No published study administers GHK-Cu and BPC-157 together. Four search routes tested that claim. The combined-term search returns the seven reviews, a broader synonym search returns the same seven, and a combination-term search returns nothing.
Open web searches do return head-to-head and stack content. All of it is retail material published by sellers, and none cites a primary study.
A product containing both is a formulation decision, not evidence of a combined effect, because no experiment has measured one. Our GLOW article covers what a blend label can and cannot establish.
GHK-Cu's status splits by route and BPC-157 never made the list
The FDA nominations document updated 14 May 2026 lists an entry under 503A Category 1, Bulk Drug Substances Under Evaluation. It reads "GHK-Cu (except for injectable routes of administration)".
That qualifier carries the whole meaning. The FDA page on substances that may present significant safety risks, current as of 22 April 2026, lists the inverse scope. Its entry reads "GHK-Cu (for injectable routes of administration)", and it sits in the table for substances nominated but withdrawn. The stated concerns are risk for immunogenicity, aggregation and peptide-related impurities, and limited data in humans.
How it arrived there is documented. GHK-Cu left Category 1 on 22 April 2026 when its nominations were withdrawn. On 5 May 2026 a nominator clarified it had meant to withdraw only the injectable route, and the substance was added back.
Our peptide legality guide explains the 503A category system. BPC-157 has no entry in any category of the nominations document. It appears in the same nominated-but-withdrawn table as injectable GHK-Cu. Neither compound sits on a live Category 2 list, and neither is on the 503A Bulks List, which would require formal rulemaking.
An advisory committee considered BPC-157 in July 2026 and reportedly voted in favour of listing it. The FDA's own briefing, dated 11 May 2026, stated the evaluation criteria weigh against placing both the free base and the acetate on the list. No official tally has been published. The vote is advisory, and no final decision exists.
Ahead of that, the FDA will consult the Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027. Cathelicidin, dihexa acetate, melanotan II and PEG-MGF are named with it. No date is set, no Federal Register notice has published, and no docket or briefing material exists.
Across the border, Health Canada published an advisory on 9 April 2026 naming both compounds among seized unauthorised injectable peptide drugs. A Type I recall followed on 5 May 2026, covering both powders as unauthorised active pharmaceutical ingredients.
On the 2026 WADA Prohibited List, BPC-157 is named explicitly under S0, non-approved substances. GHK-Cu is named nowhere on that list. S0 operates as a catch-all over any substance the list does not otherwise address. Absence from it is not a statement that a compound is permitted. Our drug-testing article separates prohibition from what panels analyse. The 2027 list takes effect on 1 January 2027 and names peptides generally as examples within S0.
A policy called the Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94, remains pending at OIRA with no public text.
What a copper certificate proves that a BPC-157 certificate cannot
The analytical question differs for each compound, and it is one of the few real distinctions available.
GHK-Cu is a copper complex, and that matters here. HPLC purity measures what fraction of the peptide-related material is the target peptide, and it cannot show whether copper remains coordinated. Identity needs mass spectrometry confirming the intact complex. For BPC-157 the analogous question is salt form, because free base and acetate carry different formula weights. Both are supplied as research material, on the GHKCU and BPC-157 pages.
Neither answer reaches as far as it looks. A certificate, HPLC result or purity percentage never establishes safety, efficacy or equivalence to study material. Our COA reading guide covers what those documents mean.
Skin, tendon or gut questions, matched to the tier that actually exists
Different research questions meet very different evidence here, and naming a winner would hide that.
A question about human skin after laser resurfacing has a randomised trial behind it, and that trial found nothing on its objective endpoints. Gastrointestinal mucosal injury has animal data on the BPC-157 side only, some from independent groups. Tendon healing has rodent data on both sides that cannot be lined up.
TB-500 belongs to the same comparison set, covered in our BPC-157 vs TB-500 article. Some questions have no usable evidence at all. Hair growth has no record isolating GHK-Cu. Human tendon outcomes have no controlled trial for either compound. Combined use has no experiment of any kind.
The bottom line
What is established here is narrow. GHK-Cu reached human trials and the two largest returned null results on their objective endpoints. BPC-157 has a large animal literature, five small human studies, no identified receptor and an unreported Phase 1.
Most of what gets claimed for both remains unestablished. Seven reviews put them side by side, and no experiment has given both.
One adequately powered, independently run human trial of either compound would settle more than four decades of mechanistic work has.
